search
Back to results

European Study Evaluating the EMBLOK Embolic Protection System During TAVR

Primary Purpose

Aortic Valve Disease

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Transcatheter Aortic Valve Replacement (TAVR)
EMBLOK filter
Sponsored by
Innovative Cardiovascular Solutions
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Aortic Valve Disease

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subject is between 18 and 90 years of age.Subject is scheduled to undergo transcatheter aortic valve replacement (TAVR) procedure on a native aortic valve and is qualified based on pre-operative trans-thoracic echocardiogram (TTE). Subject anatomy is compatible with correct device positioning with: Iliofemoral access compatible with a 12 French arterial access system for the EMBLOK catheter (> 4 mm vessel diameter). Ascending aorta length greater than or equal to 9 cm. Ascending aorta/aortic arch diameter less than or equal to 35mm.

Female subjects of child bearing potential must have a negative pregnancy test within 48 hours prior to the index study procedure.Subject agrees to comply with all study required visits. Subject or subject's legal representative completes written Informed Consent.

Exclusion Criteria: Subject requires an emergent procedure. Contraindications to MRI including: Subjects with any non-MRI compatible implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVI procedure, claustrophobia, planned implantation of non-MRI compatible pacemaker or implantable cardioverter defibrillator within 30 days after TAVR.

Subject has experienced a myocardial infarction within 30 days of the planned index procedure.

Subject has renal insufficiency, defined as a creatinine level > 2.5 mg/dl at the time of treatment.

Subject has documented history of stroke or TIA within prior 3 months. Subject has an ejection fraction of 30% or less. Subject has a history of intolerance, allergic reaction or contraindication to any of the study medications, including heparin, aspirin, clopidogrel or a sensitivity to contrast media or anesthesia which cannot be adequately pre-treated.

Subject has known allergy to any materials used in the EMBLOK device or allergy to intravascular contrast agents that cannot be pre-medicated.

Subject has active endocarditis or an ongoing systemic infection defined as fever within temperature > 38° C and/ or WBC > 15,000 IU.

Subjects undergoing therapeutic thrombolysis. Subject has history of bleeding diathesis or a major coagulopathy. Subject is known or suspected to be pregnant, or is lactating. Subject is currently participating in another drug or device clinical study, or has other medical illnesses that may cause the subject to be non-compliant with the protocol or confound the data interpretation.

Sites / Locations

  • Hospital San DonatoRecruiting
  • Hospital San RaffaeleRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

TAVR + Embolic protection

Arm Description

subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement

Outcomes

Primary Outcome Measures

Performance Endpoint
successful insertion, placement and removal of the EMBLOK system

Secondary Outcome Measures

Safety Endpoint (Rate of MACCE)
Rate of MACCE

Full Information

First Posted
April 11, 2017
Last Updated
May 6, 2021
Sponsor
Innovative Cardiovascular Solutions
Collaborators
Meditrial Europe Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03130491
Brief Title
European Study Evaluating the EMBLOK Embolic Protection System During TAVR
Official Title
European Study Evaluating the EMBLOK Cerebral Embolic Protection System During Transcatheter Aortic Valve Replacement (TAVR)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 8, 2017 (Actual)
Primary Completion Date
October 10, 2021 (Anticipated)
Study Completion Date
December 10, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innovative Cardiovascular Solutions
Collaborators
Meditrial Europe Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective is to evaluate the performance and the treatment effect of the use of the Emblok embolic protection system use during transcatheter aortic valve replacement with respect to procedure-related cerebral embolic burden as determined by DW-MRI.
Detailed Description
The enrollment of up to thirty subjects with severe native aortic valve stenosis who meet clinically approved indications for transcatheter aortic valve replacement. The primary objective evaluates performance and treatment effect of the use of the EMBLOK. A secondary objective of this study is to analyze the safety profile and the type of captured debris from the Emblok filter after TAVR. Due to the small sample size, the study is not powered to detect a reduction in actual stroke rates. However, the potential risk of stroke will be assessed based on neurological evaluations pre and post procedure. In addition, silent ischemic damage and cerebral embolic burden will be assessed using DW MRI studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Disease

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TAVR + Embolic protection
Arm Type
Other
Arm Description
subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
Intervention Type
Procedure
Intervention Name(s)
Transcatheter Aortic Valve Replacement (TAVR)
Intervention Description
placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
Intervention Type
Device
Intervention Name(s)
EMBLOK filter
Intervention Description
Embolic Filter Protection System During TAVR
Primary Outcome Measure Information:
Title
Performance Endpoint
Description
successful insertion, placement and removal of the EMBLOK system
Time Frame
Day 1 to post procedure
Secondary Outcome Measure Information:
Title
Safety Endpoint (Rate of MACCE)
Description
Rate of MACCE
Time Frame
30 days
Other Pre-specified Outcome Measures:
Title
Efficacy Endpoint
Description
Reduction in embolic burden as measured by DW-MRI at baseline compared to post procedure 2-5 days
Time Frame
2-5 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is between 18 and 90 years of age.Subject is scheduled to undergo transcatheter aortic valve replacement (TAVR) procedure on a native aortic valve and is qualified based on pre-operative trans-thoracic echocardiogram (TTE). Subject anatomy is compatible with correct device positioning with: Iliofemoral access compatible with a 12 French arterial access system for the EMBLOK catheter (> 4 mm vessel diameter). Ascending aorta length greater than or equal to 9 cm. Ascending aorta/aortic arch diameter less than or equal to 35mm. Female subjects of child bearing potential must have a negative pregnancy test within 48 hours prior to the index study procedure.Subject agrees to comply with all study required visits. Subject or subject's legal representative completes written Informed Consent. Exclusion Criteria: Subject requires an emergent procedure. Contraindications to MRI including: Subjects with any non-MRI compatible implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVI procedure, claustrophobia, planned implantation of non-MRI compatible pacemaker or implantable cardioverter defibrillator within 30 days after TAVR. Subject has experienced a myocardial infarction within 30 days of the planned index procedure. Subject has renal insufficiency, defined as a creatinine level > 2.5 mg/dl at the time of treatment. Subject has documented history of stroke or TIA within prior 3 months. Subject has an ejection fraction of 30% or less. Subject has a history of intolerance, allergic reaction or contraindication to any of the study medications, including heparin, aspirin, clopidogrel or a sensitivity to contrast media or anesthesia which cannot be adequately pre-treated. Subject has known allergy to any materials used in the EMBLOK device or allergy to intravascular contrast agents that cannot be pre-medicated. Subject has active endocarditis or an ongoing systemic infection defined as fever within temperature > 38° C and/ or WBC > 15,000 IU. Subjects undergoing therapeutic thrombolysis. Subject has history of bleeding diathesis or a major coagulopathy. Subject is known or suspected to be pregnant, or is lactating. Subject is currently participating in another drug or device clinical study, or has other medical illnesses that may cause the subject to be non-compliant with the protocol or confound the data interpretation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Monica Tocchi
Phone
+41791054396
Email
monica@meditrial.eu
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Minarsch
Phone
+9492805700
Email
laura22@mmc-medical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Azeem Latib, MD
Organizational Affiliation
Hospital San Raffaele
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital San Donato
City
Milan
State/Province
Milano
ZIP/Postal Code
20097
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Federico De Marco, MD
Phone
+393286242014
Email
federico.demarco@gmail.com
First Name & Middle Initial & Last Name & Degree
Giovanni Bianchi
Phone
+393286242014
Email
giova30.bianchi@yahoo.it
First Name & Middle Initial & Last Name & Degree
Federico DeMarco, MD
Facility Name
Hospital San Raffaele
City
Milan
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vega Rusconi
Phone
+39026437331
Email
rusconi.vega@hsr.it
First Name & Middle Initial & Last Name & Degree
paolo vezzulli
Phone
+390226437331
Email
vezzulli.paolo@hsr.it
First Name & Middle Initial & Last Name & Degree
Matteo Montorfano, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32273098
Citation
Latib A, Mangieri A, Vezzulli P, Spagnolo P, Sardanelli F, Fellegara G, Pagnesi M, Giannini F, Falini A, Gorla R, Montorfano M, Bedogni F, Colombo A, Popma J, Merhi WM, De Marco F. First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Apr 13;13(7):860-868. doi: 10.1016/j.jcin.2019.11.017.
Results Reference
derived

Learn more about this trial

European Study Evaluating the EMBLOK Embolic Protection System During TAVR

We'll reach out to this number within 24 hrs